References
- Centers for Disease ControlNational Diabetes Fact Sheet, 2007. Centers for Disease Control Web site. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf Accessed 2008 June 24.
- NathanDMClearyPABacklundJYIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetesN Engl J Med20053532643265316371630
- Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med19933299779868366922
- OhkuboYKishikawaHArakiEIntensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Res Clin Pract1995281031177587918
- United Kingdom Prospective Diabetes Study GroupIntensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet19983528378539742976
- SaydahSHFradkinJCowieCCPoor control of risk factors for vascular disease among adults with previously diagnosed diabetesJAMA200429133534214734596
- KoroCEBowlinSJBourgeoisNFedderDOGlycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary reportDiabetes Care200427172014693960
- NathanDMBuseJBDavidsonMBMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the study of DiabetesDiabetes Care20093219320318945920
- KimWEganJMThe role of incretins in glucose homeostasis and diabetes treatmentPhamacol Rev200860470512
- DruckerDJThe biology of incretin hormonesCell Metab2006315316516517403
- Toft-NielsenMBDamholtMBMadsbadSDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patientsJ Clin Endocrinol Metab2001863717372311502801
- Saxagliptin (Onglyza) for type 2 diabetesMed Lett Drugs Ther200951858619890244
- ACE Diabetes Mellitus Clinical Practice Task ForceAmerican Association on Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitusEndocr Pract200713 Suppl 1368
- HanefeldMHermanGAWuMOnce-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetesCurr Med Res Opin2007231329133917559733
- RazIHanefeldMXuLEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia2006492564257117001471
- Pi-SunyerFXSchweizerAMillsDEfficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetesDiabetes Res Clin Pract20077613213817223217
- RisticSByiersSFoleyJImproved glucaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose responseDiabetes Obes Metab2005769269816219012
- GarberAJSchweizerABaronMAVildagliptin in combination with pioglitazone improves glycemic control in patients with type 2 diabetes failing thiozolidinedione monotherapy: a randomized, placebo-controlled studyDiabetes Obes Metab2007916617417300592
- RosenstockJAguilar-SalinasCKleinECV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetesCurr Med Res Opin2009252401241119650754
- JadzinskyMPfutznerAPaz-PachecoEfor the CV181-039 InvestigatorsSaxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trialDiabetes Obes Metab20091161162219515181
- DeFronzoRAHissaNMGarberAJThe efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin aloneDiabetes Care2009321649165519478198
- ChacraARTanGHApanovitchACV181-040 Investigators. Saxagliptin added to a submaximal dose of sulfonylurea improves glycaemic control compared with uptitration of sulfonylurea in patients with type 2 diabetes: a randomized controlled trialInt J Clin Pract2009631395140619614786
- HollanderPLiJAllenEChenRCV181-013 InvestigatorsSaxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione aloneJ Clin Endocrinol Metab2009944810481919864452
- RosenstockJSankohSListJFGlucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetesDiabetes Obes Metab20081037638618355324